2018
Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End‐of‐Life Care
Wang S, Hsu SH, Huang S, Doan KC, Gross CP, Ma X. Regional Practice Patterns and Racial/Ethnic Differences in Intensity of End‐of‐Life Care. Health Services Research 2018, 53: 4291-4309. PMID: 29951996, PMCID: PMC6232508, DOI: 10.1111/1475-6773.12998.Peer-Reviewed Original ResearchConceptsIntensity of endHospital referral regionsRegional practice patternsPractice patternsLife careEthnic differencesLife care expendituresLocal practice patternsCancer decedentsMedicare databaseRacial/Ethnic DifferencesReferral regionsCare expendituresCareEnd resultDifferencesEpidemiologyDecedentsPhysician peer group characteristics and timeliness of breast cancer surgery
Bachand J, Soulos PR, Herrin J, Pollack CE, Xu X, Ma X, Gross CP. Physician peer group characteristics and timeliness of breast cancer surgery. Breast Cancer Research And Treatment 2018, 170: 657-665. PMID: 29693229, PMCID: PMC6048589, DOI: 10.1007/s10549-018-4789-8.Peer-Reviewed Original ResearchConceptsPhysician peer groupsSurgical delayProvider densityPatient racial compositionBreast cancerEnd Results-Medicare dataBreast cancer patientsBreast cancer surgeryResultsThe study sampleConclusionsThe likelihoodBlack patientsCancer surgeryCancer patientsSurgeryPatientsStudy sampleWomenCancerAssociationGroupGroup characteristicsPurposeLittleInterdisciplinary groupPeer groupEpidemiology
2016
Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study
Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394. DOI: 10.1182/blood.v128.22.394.394.Peer-Reviewed Original ResearchChronic myelomonocytic leukemiaMyelodysplastic syndromeSurvival benefitHigh-risk myelodysplastic syndromeDemonstrated survival benefitRetrospective cohort studyRisk myelodysplastic syndromesUse of HMAsAgent azacitidineLack of evidenceCohort studyClinical entityMyelomonocytic leukemiaBiologic evidenceOlder adultsAzacitidineUnited StatesHMAsEnd resultPatientsSyndromeLeukemiaDecitabineEpidemiology